Valence ロゴ
人気
ログイン

ウォッチリストに追加
Proチャート

Erasca Inc.

NasdaqGS: ERAS · リアルタイム株価 · USD
18.38
+0.52 (2.91%)
終値時点： Aug 14, 2026, 3:59 PM
18.26
-0.65%
時間外: 7:34 PM

Erasca Inc. (ERAS) Stock Price, Analysis & Data

2.91%
買気配13.16
時価総額6.43B
売上高（TTM）n/a
純利益（TTM）-287.22M
ベータ0.65
EPS（TTM）-0.95
PER（TTM）n/a
予想PER-31.59
PBR（TTM）14.52
PSR（TTM）n/a
Earnings DateNov 11, 2026
売気配22.15
出来高2,462,124
平均出来高（20日）4,970,445
始値17.56
前日終値17.86
当日レンジ17.30 - 18.46
52週レンジ1.33 - 24.28
アナリストBuy
目標株価23 (25.14%)
配当n/a
権利落ち日n/a

ERASについて

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Jul 16, 2021
従業員数 103
上場取引所 NasdaqGS
ティッカー ERAS
ウェブサイト https://www.erasca.com
企業情報の全文

業績

2025年のErascaの売上高は0で、前年の0からundefined%の増加でした。 利益は-124.55Mで、-22.95%の減少でした。

財務諸表

アナリスト予想

9件のアナリスト評価によると、ERAS株の平均レーティングは「Buy」です。12か月後の目標株価は23で、直近株価から25.14%の上昇余地となります。

株価予想

決算サプライズ

ErascaはAug 11, 2026に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -0.14 で、予想を下回りました -0.03, うち -16.67% の前年比減少.

    • 次回決算発表

    Erasca Inc.の決算発表予定日は Nov 11, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1か月前 · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    1か月前 · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    1か月前 · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    1か月前 · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    1か月前 · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    2ページ中1ページ